Literature DB >> 22634441

Parental views on vaccine safety and future vaccinations of children who experienced an adverse event following routine or seasonal influenza vaccination in 2010.

Adriana Parrella1, Michael Gold, Helen Marshall, Annette Braunack-Mayer, Maureen Watson, Peter Baghurst.   

Abstract

To assess parental vaccine safety views and future vaccination decisions after an adverse event following immunization (AEFI) experienced by their child. A cross-sectional telephone survey was conducted of parents of children aged 0-7 y, identified in AEFI reports submitted to the South Australian Immunization Section, Department Health. The reports included childhood National Immunization Program (NIP), seasonal or pandemic influenza vaccines. Interviews were conducted following a national suspension of the 2010 seasonal trivalent influenza (STIV) vaccine. Parental attitudes toward vaccine safety, reasons for reporting the AEFI and impact on future vaccination intent were assessed. Of 179 parents interviewed, 88% were confident in the safety of vaccines in general. Parents reporting an AEFI to the STIV were more likely to state the event had influenced future vaccination decisions than the NIP vaccine reporters (65% vs 14%, p < 0.001), with 63% stating refusal or hesitance to re-vaccinate their children against influenza. Media reports of the 2010 STIV program suspension was the most common reason for reporting an AEFI for parents of children who received an influenza vaccination. The AEFI experience did not impact on parental decision to continue with routine childhood NIP schedules, regardless of whether children received influenza or NIP vaccines. In contrast, most parents whose child experienced an AEFI to the 2010 STIV stated decreased confidence in the safety of influenza vaccines, which is likely to have impacted on the uptake of seasonal influenza vaccination in 2011. Addressing influenza vaccine safety concerns to promote influenza vaccination in the community is required.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22634441     DOI: 10.4161/hv.19478

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  6 in total

1.  Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.

Authors:  Hazel J Clothier; Nigel W Crawford; Melissa Russell; Heath Kelly; Jim P Buttery
Journal:  Drug Saf       Date:  2017-06       Impact factor: 5.606

2.  Consumer reporting of adverse events following immunization (AEFI): identifying predictors of reporting an AEFI.

Authors:  Adriana Parrella; Michael Gold; Annette Braunack-Mayer; Peter Baghurst; Helen Marshall
Journal:  Hum Vaccin Immunother       Date:  2014-01-09       Impact factor: 3.452

3.  Canadian paediatricians' approaches to managing patients with adverse events following immunization: The role of the Special Immunization Clinic network.

Authors:  Karina A Top; Joseline Zafack; Gaston De Serres; Scott A Halperin
Journal:  Paediatr Child Health       Date:  2014-06       Impact factor: 2.253

4.  The impact of a vaccine scare on parental views, trust and information needs: a qualitative study in Sydney, Australia.

Authors:  Catherine King; Julie Leask
Journal:  BMC Public Health       Date:  2017-01-23       Impact factor: 3.295

5.  Parents' and adolescents' willingness to be vaccinated against serogroup B meningococcal disease during a mass vaccination in Saguenay-Lac-St-Jean (Quebec).

Authors:  Eve Dubé; Dominique Gagnon; Denis Hamel; Sylvie Belley; Hélène Gagné; Nicole Boulianne; Monique Landry; Julie A Bettinger
Journal:  Can J Infect Dis Med Microbiol       Date:  2015 May-Jun       Impact factor: 2.471

6.  Healthcare providers' knowledge, experience and challenges of reporting adverse events following immunisation: a qualitative study.

Authors:  Adriana Parrella; Annette Braunack-Mayer; Michael Gold; Helen Marshall; Peter Baghurst
Journal:  BMC Health Serv Res       Date:  2013-08-15       Impact factor: 2.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.